Published in Pharmaceuticals (Basel) on April 17, 2013
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 45.46
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med (2012) 35.24
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med (2011) 26.90
PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol (2008) 19.24
Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol (2010) 17.13
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature (2010) 15.63
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet (2012) 13.89
Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature (2006) 13.75
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med (2012) 13.48
Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med (2012) 11.72
High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol (1999) 10.86
Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol (2008) 10.13
Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol (1996) 6.79
Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol (2009) 6.44
Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med (2012) 6.17
Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med (2012) 6.01
The PD-1-PD-L pathway in immunological tolerance. Trends Immunol (2006) 4.52
Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol (2012) 4.52
PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells. Pigment Cell Melanoma Res (2010) 4.50
Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Invest Dermatol (2008) 4.18
Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group. J Clin Oncol (2008) 3.58
Adalimumab for the treatment of moderate to severe Hidradenitis suppurativa: a parallel randomized trial. Ann Intern Med (2012) 3.14
Possible pathogenic role of Th17 cells for atopic dermatitis. J Invest Dermatol (2008) 3.11
Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med (2010) 2.74
Treatment of chronic autoimmune urticaria with omalizumab. J Allergy Clin Immunol (2008) 2.68
Sarcoidosis is a Th1/Th17 multisystem disorder. Thorax (2010) 2.60
BRAF inhibitor activity in V600R metastatic melanoma. Eur J Cancer (2012) 2.55
Phase I/II trial of tremelimumab in patients with metastatic melanoma. J Clin Oncol (2009) 2.53
Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma. J Clin Oncol (2012) 2.42
Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial. Lancet (2012) 2.34
A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res (2004) 2.28
Cutaneous adverse events associated with vemurafenib in patients with metastatic melanoma: practical advice on diagnosis, prevention and management of the main treatment-related skin toxicities. Br J Dermatol (2012) 2.23
Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma. Clin Cancer Res (2010) 2.20
Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents. Inflamm Bowel Dis (2007) 2.08
International trends in the incidence of malignant melanoma 1953-2008--are recent generations at higher or lower risk? Int J Cancer (2012) 2.07
Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis. Br J Pharmacol (2009) 1.89
The prevalence of psoriatic arthritis in people with psoriasis. Arthritis Rheum (2009) 1.84
Anti-CD20 (rituximab) treatment improves atopic eczema. J Allergy Clin Immunol (2008) 1.82
Treatment of pityriasis rubra pilaris with ustekinumab. Br J Dermatol (2010) 1.70
A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria. J Allergy Clin Immunol (2011) 1.64
Interleukin 23 expression in pyoderma gangrenosum and targeted therapy with ustekinumab. Arch Dermatol (2011) 1.62
A randomized controlled evaluator-blinded trial of intravenous immunoglobulin in adults with severe atopic dermatitis. Br J Dermatol (2002) 1.52
Prevalence of joint disease in patients with psoriasis: implications for therapy. Am J Clin Dermatol (2003) 1.48
Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study. Br J Dermatol (2012) 1.42
The multitasking organ: recent insights into skin immune function. Immunity (2011) 1.38
Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma. Br J Dermatol (2012) 1.33
Treatment of chronic spontaneous urticaria. Allergy Asthma Immunol Res (2012) 1.32
Phase II Trial of Temozolomide and Sorafenib in Advanced Melanoma Patients with or without Brain Metastases. Clin Cancer Res (2009) 1.30
Sorafenib: a clinical and pharmacologic review. Expert Opin Pharmacother (2010) 1.29
The PKC inhibitor AEB071 may be a therapeutic option for psoriasis. J Clin Invest (2008) 1.27
Chronic urticaria and autoimmunity: associations found in a large population study. J Allergy Clin Immunol (2012) 1.21
Elevated levels of tumour necrosis factor (TNF)-α, interleukin (IL)-1β and IL-10 in hidradenitis suppurativa skin: a rationale for targeting TNF-α and IL-1β. Br J Dermatol (2011) 1.14
IFN-α in the treatment of melanoma. J Immunol (2012) 1.12
The clinical and histomorphological features of pityriasis rubra pilaris. A comparative analysis with psoriasis. J Cutan Pathol (1997) 1.11
Phase II study of the Src kinase inhibitor saracatinib (AZD0530) in metastatic melanoma. Invest New Drugs (2012) 1.09
Pentoxifylline inhibits TNF-alpha production from human alveolar macrophages. Am J Respir Crit Care Med (1999) 1.06
Profile of alopecia areata: a questionnaire analysis of patient and family. Int J Dermatol (1992) 1.06
Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients. J Transl Med (2012) 1.06
Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with ipilimumab (MDX-010). Oncologist (2008) 1.05
Combination of MEK and SRC inhibition suppresses melanoma cell growth and invasion. Oncogene (2012) 1.04
Omalizumab for chronic urticaria: a case series and overview of the literature. Case Rep Dermatol (2012) 1.03
Altered innate and adaptive immune responses in patients with hidradenitis suppurativa. Br J Dermatol (2007) 1.02
Abnormal expression of class I and class II major histocompatibility antigens in alopecia areata: modulation by topical immunotherapy. J Invest Dermatol (1987) 1.02
Tumour necrosis factor alpha is pro-inflammatory in normal human skin and modulates cutaneous adhesion molecule expression. Br J Dermatol (1995) 1.02
Treatment of recalcitrant pemphigus vulgaris with the tumor necrosis factor alpha antagonist etanercept. Cutis (2004) 1.01
Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab' certolizumab pegol: results of a phase II randomized, placebo-controlled trial with a re-treatment extension. Br J Dermatol (2012) 1.01
Expression of the IL-23/Th17 pathway in lesions of hidradenitis suppurativa. J Am Acad Dermatol (2011) 1.00
Infliximab in the treatment of moderate to severe atopic dermatitis. J Am Acad Dermatol (2005) 1.00
Intravenous anti-IL-5 monoclonal antibody reduces eosinophils and tenascin deposition in allergen-challenged human atopic skin. J Invest Dermatol (2004) 0.99
Recombinant interferon gamma therapy for atopic dermatitis. J Am Acad Dermatol (1993) 0.97
Double anti-angiogenic and anti-inflammatory protein Valpha targeting VEGF-A and TNF-alpha in retinopathy and psoriasis. J Biol Chem (2011) 0.96
A randomized, double-blind, placebo-controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasis. Br J Dermatol (2012) 0.96
Successful treatment of type 1 pityriasis rubra pilaris with ustekinumab therapy. Eur J Dermatol (2010) 0.96
Psoriatic arthritis treatment: biological response modifiers. Ann Rheum Dis (2005) 0.96
The effect of infliximab on extraintestinal manifestations of Crohn's disease. Rheumatol Int (2004) 0.93
Efficacy of omalizumab in the treatment of atopic dermatitis: a pilot study. Allergy Asthma Proc (2008) 0.93
Omalizumab is effective in nonautoimmune urticaria. J Allergy Clin Immunol (2011) 0.91
Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation. Health Technol Assess (2006) 0.91
Resistance to alopecia areata in C3H/HeJ mice is associated with increased expression of regulatory cytokines and a failure to recruit CD4+ and CD8+ cells. J Invest Dermatol (2002) 0.91
Rapid control of therapy-refractory pemphigus vulgaris by treatment with the tumour necrosis factor-alpha inhibitor infliximab. Br J Dermatol (2005) 0.91
The treatment of atopic dermatitis with adjunctive high-dose intravenous immunoglobulin: a report of three patients and review of the literature. Br J Dermatol (2000) 0.91
Low-dose rituximab is effective in pemphigus. Br J Dermatol (2012) 0.91
Etanercept for chronic progressive cutaneous sarcoidosis. J Drugs Dermatol (2006) 0.91
BRIM-1, -2 and -3 trials: improved survival with vemurafenib in metastatic melanoma patients with a BRAF(V600E) mutation. Future Oncol (2012) 0.91
Clinical improvement and immunohistochemical findings in severe atopic dermatitis treated with interferon gamma. J Am Acad Dermatol (2000) 0.89
Simultaneous targeting of TNF and Ang2 with a novel bispecific antibody enhances efficacy in an in vivo model of arthritis. MAbs (2012) 0.89
Safety profile and pharmacokinetic analyses of the anti-CTLA4 antibody tremelimumab administered as a one hour infusion. J Transl Med (2012) 0.87
Efalizumab for severe atopic dermatitis: a pilot study in adults. J Am Acad Dermatol (2006) 0.85
Infliximab monotherapy as first-line treatment for adult-onset pityriasis rubra pilaris: case report and review of the literature on biologic therapy. J Am Acad Dermatol (2008) 0.85
Adjunctive high-dose intravenous immunoglobulin treatment for resistant atopic dermatitis: efficacy and effects on intracellular cytokine levels and CD4 counts. Acta Derm Venereol (2003) 0.84
Management of recalcitrant hidradenitis suppurativa with ustekinumab. Acta Derm Venereol (2012) 0.84
Pityriasis rubra pilaris presenting with an abnormal autoimmune profile: two case reports. J Med Case Rep (2009) 0.83
Two cases of chronic atopic dermatitis treated with soluble tumor necrosis factor receptor therapy. J Drugs Dermatol (2009) 0.83
Sleep quality and other patient-reported outcomes improve after patients with psoriasis with suboptimal response to other systemic therapies are switched to adalimumab: results from PROGRESS, an open-label Phase IIIB trial. Br J Dermatol (2012) 0.83
Blood eosinophils and serum IgE as predictors for prognosis of interferon-gamma therapy in atopic dermatitis. Allergy (1998) 0.82
Subcutaneous efalizumab is not effective in the treatment of alopecia areata. J Am Acad Dermatol (2008) 0.82
An update on the long-term safety experience of ustekinumab: results from the psoriasis clinical development program with up to four years of follow-up. J Drugs Dermatol (2012) 0.82
Type I pityriasis rubra pilaris: upregulation of tumor necrosis factor alpha and response to adalimumab therapy. J Cutan Med Surg (2010) 0.82
Exploring the Psychological Profile of Patients with Delusional Infestation. Acta Derm Venereol (2017) 0.75
Ustekinumab for the treatment of psoriatic arthritis. Expert Rev Clin Pharmacol (2014) 0.75
Atypical Trigeminal Trophic Syndrome: An Unusual Cause of Facial Ulceration. Acta Derm Venereol (2017) 0.75
Social anxiety disorder and agoraphobia in dermatology patients; two cases and a review of the literature. Acta Derm Venereol (2015) 0.75
Later Age of Onset and Longer Duration of Untreated Psychosis are Associated with Poorer Outcome in Delusional Infestation. Acta Derm Venereol (2020) 0.75
Psychodermatology in Clinical Practice: Main Principles. Acta Derm Venereol (2016) 0.75